Science to practice
Latest highlights on drug safety and efficacy

22.1.2025

Valproic acid is a well-known teratogen, and maternal valproic acid use during pregnancy is associated with long-term offspring neurodevelopmental disorders and cognitive disturbances. The manufacturer also warns about male infertility. Lately, concerns have been raised by drug authorities in the EU and UK regarding possibility of paternally mediated disturbances of neurodevelopment.

However, in a large Danish registry study, there was no association of paternal pre-conception use of valproate with offspring risk of congenital malformations or neurodevelopmental disorders (1). Furthermore, a recent systematic review did not find any clear evidence for adverse effects of paternal exposure to antiseizure medications, including valproic acid, on offspring outcomes. The authors conclude that there is no justification for major concerns (2).

Recent research indicates no evidence linking paternal valproic acid use before conception to increased risks of congenital malformations or neurodevelopmental disorders in offspring.

For comprehensive insights into drug safety and efficacy during pregnancy and lactation, explore our databases Gravbase and Lactbase.

News produced by Medbase Medical Team

References

1. Christensen J, Trabjerg BB, Dreier JW. Valproate Use During Spermatogenesis and Risk to Offspring. JAMA Netw Open. 2024 Jun 3;7(6):e2414709. PMID: 38833248
2. Honybun E, Rayner G, Malpas CB, O’Brien TJ, Vajda FJ, Perucca P, Perucca E. Paternal exposure to antiseizure medications and offspring outcomes: a systematic review. J Neurol Neurosurg Psychiatry. 2024 Dec 16;96(1):15-25. PMID: 39299778.